Literature DB >> 1700756

Polarity of immunogens: implications for vaccine design.

J Golvano1, J J Lasarte, P Sarobe, A Gullón, J Prieto, F Borrás-Cuesta.   

Abstract

Peptide constructs have been engineered consisting of amino acid sequence determinant recognized by T cells (TD) co-linearly linked to haptenic peptides. It was found that high anti-hapten antibody titers were induced after immunization with those constructs which had the TD sequence in the N-terminal position with respect to the hapten. Low or zero titers were elicited when the TD was in C-terminal position. Also, a high anti-hapten antibody titer corresponded to a low or zero anti-TD antibody titer and vice versa. These results suggest that immunogens are polar and stress the relevance of searching the more adequate position of the TD within a peptide construct when designing immunogens or synthetic peptide vaccines.

Mesh:

Substances:

Year:  1990        PMID: 1700756     DOI: 10.1002/eji.1830201031

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

Review 1.  Human cartilage proteoglycans as T cell autoantigens.

Authors:  J A Goodacre; J P Pearson
Journal:  Ann Rheum Dis       Date:  1992-09       Impact factor: 19.103

2.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

3.  Mapping of specific and promiscuous HLA-DR-restricted T-cell epitopes on the Plasmodium falciparum 27-kilodalton sexual stage-specific antigen.

Authors:  C E Contreras; I N Ploton; R F Siliciano; C L Karp; R Viscidi; N Kumar
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

4.  Towards the design of heterovalent anti-malaria vaccines: a hybrid immunogen capable of eliciting immune responses to epitopes of circumsporozoite antigens from two different species of the malaria parasite, Plasmodium.

Authors:  F A Kironde; K V Rao; S Shah; A Kumar; N Sahoo
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

5.  A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants.

Authors:  O Taboga; C Tami; E Carrillo; J I Núñez; A Rodríguez; J C Saíz; E Blanco; M L Valero; X Roig; J A Camarero; D Andreu; M G Mateu; E Giralt; E Domingo; F Sobrino; E L Palma
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

Authors:  I M Fernández; A Snijders; B J Benaissa-Trouw; M Harmsen; H Snippe; C A Kraaijeveld
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

7.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

8.  Human cartilage aggrecan CS1 region contains cryptic T-cell recognition sites.

Authors:  J A Goodacre; S Middleton; S Lynn; D A Ross; J Pearson
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

9.  Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.

Authors:  E A de Velasco; D Merkus; S Anderton; A F Verheul; E F Lizzio; R Van der Zee; W Van Eden; T Hoffman; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

10.  Induction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigens.

Authors:  A Bharadwaj; P Sharma; S K Joshi; B Singh; V S Chauhan
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.